Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
31.37
+0.42 (1.37%)
Oct 29, 2026, 11:00 AM EDT - Market open
Vera Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Vera Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $74.2. The average 1-year stock price forecast is 136.57% higher than the current stock price, while the lowest is $34 (+8.40%) and the highest is $100 (+218.83%).
Price Target: $74.2 (+136.57%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Vera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 12 | 12 | 12 | 12 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 14 | 14 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Leerink Partners No rating | Leerink Partners | Hold Maintains $34 | Hold | Maintains | $34 | +8.40% | Oct 27, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Reiterates $80 | Buy | Reiterates | $80 | +155.06% | Oct 23, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $100 | Buy | Maintains | $100 | +218.83% | Oct 23, 2026 |
| Wedbush | Wedbush | Hold Maintains $34 | Hold | Maintains | $34 | +8.40% | Oct 23, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $76 | Buy | Reiterates | $76 | +142.31% | Oct 23, 2026 |
Financial Forecast
Revenue This Year
24.83M
Revenue Next Year
233.76M
from 24.83M
Increased by 841.44%
EPS This Year
-6.25
from -4.66
EPS Next Year
-4.25
from -6.25
EPS and Forward PE are based on non-GAAP adjusted numbers.